Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity.
Anaphylaxis or significant hypersensitivity reaction is one of the most catastrophic potential complications of chemotherapy. There is a 2-5% risk of hypersensitivity with paclitaxel, a commonly used chemotherapeutic agent for various cancers. Three patients, who developed hypersensitivity to paclitaxel infusion, received docetaxel without allergic reactions. Docetaxel may therefore be an alternative treatment for patients with paclitaxel hypersensitivity.
Moon
C
C
Department of Internal Medicine Specialities, University of Texas MD Anderson Cancer Center, Houston 77030, USA.
Verschraegen
C F
CF
Bevers
M
M
Freedman
R
R
Kudelka
A P
AP
Kavanagh
J J
JJ
D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects* / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D002927:Cimetidine / Q000627:therapeutic use; D003536:Cystadenocarcinoma / Q000188:drug therapy*; D003907:Dexamethasone / Q000627:therapeutic use; D004155:Diphenhydramine / Q000627:therapeutic use; D000077143:Docetaxel; D004334:Drug Administration Schedule; D004342:Drug Hypersensitivity / Q000209:etiology* / Q000517:prevention & control; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D043823:Taxoids
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D003907:Dexamethasone; D002927:Cimetidine; D004155:Diphenhydramine; D017239:Paclitaxel